CDER Permits Some Combo Product Software To Be Submitted As DMFs
Executive Summary
New draft guidance allows electronics or software that will be used across multiple combination products to be submitted as a Type V drug master file, potentially streamlining the assessment process.
You may also be interested in...
US FDA Hoping To Solve Drug-Software Issues With Digital Health Working Group
As more applications include software components, group wants assessors to apply best practices from CDRH to CDER whenever possible.
Combination Products: US FDA Aims For Limited Two-Application Solutions
In announcing guidance stating one application generally is sufficient for a combination product, FDA asks for comments on situations where two would be needed.
Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
But sponsors should sometimes seek advisory comment. Agency explains that most drug-use-related apps will be considered promotional labeling. FDA seeking feedback from a variety of stakeholders on its discussion proposal for regulating prescription-focused software.